RE:RE:RE:Researchers in China Acknowledge TLD1433 Safety and Efficacy SF wrote:
"Here's an excerpts that shows the feat and heavy lifting that TLT about to achieve and about to debunk the following statement:
The efficacy of combination therapy is much better than a single drug alone, which has been proved in treating unresponsive BCG or BCG-ineligible patients [100].
The big pharma that will jv with us will bring TLD1433 as a first-line therapy, with the aim of controlling the whole NMIBC spectrum, from early-stage to late-stage. No doubt. And if I was a competitor of Merck (that produces BCG and that also has FDA approval with Keytruda for BCG-unresponsive), I would shift them by doing a jv with TLT."
I believe if any Big Pharma ultimately partners with TLT (based on TLT's receipt of an AA for BCG-unresponsive NMIBC, or at least post BTD), it would be Merck imo. With Merck's recently approved Keytruda now in play, an agreement with TLT would undoubtedly enable Merck to corner the NMIBC market. I don't see Merck overlooking such a huge opportunity & allowing a superior ACT gem slip through its hands to a competitor, especially when considering it's coming from a little start-up biotech.
Merck would also more than likely presume there's a strong possibility our ACT could perform even better when used in combination with its immunotherapy, or perhaps when used as a primer treatment to enhance the response to Keytruda. We are already seeing the importance of additional boosting of the immune response as has recently been demonstrated in the N-803 & BCG trial.
Imo, Merck is becoming increasingly aware of the growing research/validation of PDT in other indications. As you know, our ol' friends at Roswell Park are currently undergoing a Ph1/2 clinical trial utilizing local PDT in the treatment of NSCLC with pleural involvement. They are specifically investigating not only its direct tumor destruction/suppressive ability, but also if local PDT can significantly enhance the response to immunotherapy with an immune checkpoint inhibitor.
If the above study is successful, this will provide an even bigger feather in our cap, considering they are using the older generation PS (Photofrin) in place of our more promising TLD-1433. All imo. Good luck...